New drug combo targets Hard-to-Treat cancers

NCT ID NCT07126665

Recruiting now Disease control Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests two experimental drugs, MHB088C and MHB039A, given together by IV to people with advanced solid tumors that no longer respond to standard treatments. The study has two stages: first, finding the safest dose, then checking if the combination can shrink tumors. About 116 adults with various advanced cancers will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MHB088C and MHB039A (two experimental drugs given by IV)
What this could lead to: If it works, this could point toward a new combination treatment for advanced solid tumors that have stopped responding to standard therapy.
What could go wrong: This is a very early, first-in-human trial with only 116 participants. The drugs may not shrink tumors or could cause serious side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT SOLID TUMOR

Contacts and locations

Locations

Ethics Committee of Shanghai East Hospital
RECRUITING

Shanghai, Shanghai Municipality, 201419, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.